Serious complications of COVID-19 vaccines: A mini-review

Paraskevi C. Fragkou a,*, Dimitra Dimopoulou b

a 1st Department of Critical Care and Pulmonary Services, Evangelismos Hospital, Medical School, National and Kapodistrian University of Athens, Greece
b 2nd Department of Pediatrics, Medical School, National and Kapodistrian University of Athens, Children’s Hospital “Panagiotis and Aglaia Kyriakou”, Athens, Greece

A R T I C L E   I N F O

Keywords:
COVID-19
Vaccines
Complications
Adverse events

A B S T R A C T

The most promising approach of fighting COVID-19 and restraining the course of this pandemic is indisputably the universal vaccination of the population with safe and effective vaccines. However, besides the common and usually mild side effects of the authorized vaccines, some rare, major adverse reactions are increasingly being reported worldwide during the post marketing surveillance phase of vaccines’ circulation, such as anaphylaxis, vaccine-induced thrombotic thrombocytopenia, myopericarditis and Guillain-Barré syndrome. Despite rare cases with complications from COVID-19 vaccines, the net benefit-risk ratio shows a clearly favorable balance towards COVID-19 vaccination for all age and sex groups. Vaccine adverse events should be identified early and monitored closely. As many aspects of these adverse effects remain still obscure for the medical community and the relevant stakeholders, it is also highly important to be promptly reported. Nonetheless, these complications should not constitute a reason to change the vaccine policy and further studies are needed to alleviate concerns and reluctance to COVID-19 vaccinations.

Since its first occurrence in December 2019, the novel coronavirus disease 2019 (COVID-19) pandemic has caused millions of deaths around the globe and, unfortunately, continues to challenge even the most resilient healthcare systems. Besides infection control measures, the most promising approach of winning the battle against the Severe Acute Respiratory Syndrome coronavirus 2 (SARS-CoV-2) and restraining the course of this pandemic is indisputably the universal vaccination of the population with safe and effective vaccines [1].

Several vaccines using distinctive technologies and platforms are in the pipeline and some of them have already been approved or granted emergency use authorization (EUA) and are administered in multiple countries globally. The first approved vaccine by the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) was the vaccine developed by the Pfizer and the BioNTech [2,3]. Currently, there are two main types of available COVID-19 vaccines: the messenger RNA (mRNA) vaccines and the vaccines utilizing a viral vector (non-replicating adenoviral strains) [4,5]. However, vaccines using inactivated SARS-CoV-2 strains have also been approved by the World Health Organization (WHO) and are available in many countries around the globe [6,7]. All types of the currently approved circulating vaccines have shown to be safe and effective in reducing the risk for severe COVID-19 infection [4,8]. Besides the common (and usually mild) side effects of the authorized vaccines, such as the low-grade fever and the pain at the injection site [8,9], some major, but thankfully, uncommon, adverse reactions are increasingly being reported during the post marketing surveillance phase [9]. Here, we briefly outline the most serious and/or rare complications of COVID-19 vaccines that have been described to date (see Table 1).

Anaphylaxis is a serious generalized allergic reaction that is characterized by rapid onset affecting the airway and/or the lower respiratory tract and/or the circulation, that may lead to death [10]. Anaphylaxis has been rarely reported after COVID-19 vaccination, with an estimated rate of 11.1 cases per million doses administered [11], with the mRNA based vaccines (BNT162b2 and mRNA-1273) being two of the vaccines with the most frequently reported cases compared to the viral vector vaccines [11–13]. Although the potential causative allergens within the COVID-19 vaccines have not been identified yet, polyethylene glycol (PEG) and polysorbate might be implicated in severe allergic reactions associated with mRNA and vector-based vaccines, respectively [14]. The clinical features of severe immediate IgE-mediated hypersensitivity reactions to COVID-19 vaccines do not differ from other anaphylactic reactions; however, other mimicking conditions such as vasovagal episodes or anxiety-related symptoms should be discriminated from true anaphylaxis [15]. Laboratory tests like tryptase levels might be useful in difficult to differentiate cases [16]. The treatment of anaphylaxis does not differ from that of severe allergic
reactions from other causes [17, 18]. For the cases with confirmed moderate and severe allergic reactions after the first vaccine dose, the administration of the second dose is not recommended, or (in the case of an mRNA vaccine first) can be substituted by a non-mRNA vaccine [17, 18].

In late February 2021, a syndrome called Thrombosis with Thrombocytopenia Syndrome (TTS) or Vaccine-induced Thrombotic Thrombocytopenia (VITT) was first reported in a small group of people in the United Kingdom (UK) who received the ChAdOx1 CoV-19 vaccine, an adenoviral vector-based vaccine developed by AstraZeneca and the University of Oxford [19, 20]. Later, similar cases of thrombosis with thrombocytopenia were also reported in individuals who were vaccinated with the adenoviral vector-based Ad26.COV2.S vaccine by Johnson & Johnson [21]. VITT usually occurs within 4–42 days following vaccination against COVID-19 and is characterized by the development of arterial and/or venous thrombosis (usually atypical such as cerebral and abdominal thrombosis), along with low platelet count, high d-dimers (>4 times the upper limit of normal) and positive antibodies against the platelet factor 4 (PF4, positive PF4-heparin ELISA) [21]. Although a single case of VITT has also been reported post-vaccination with the mRNA-1273 vaccine that was developed by the Moderna company, the vast majority of these cases occur after administration of Ad26.COV2.S or ChAdOx1 CoV-19 vaccines; interestingly, other adenoviral vector-based vaccines (such as the Gam-COVID-Vac/Sputnik V by Gamaleya Institute) have not been implicated in the development of the syndrome [22]. The exact incidence of this novel entity remains unknown. However, it is estimated that it occurs in 0.73 per 100,000 individuals [95% confidence interval

### Table 1
Characteristics of the serious complications caused by COVID-19 vaccines.

| Vaccine Complications | Most Common Vaccine Type | Incidence | Possible pathogenetic mechanisms | Clinical presentation | Special Considerations for treatment or prevention |
|------------------------|--------------------------|-----------|----------------------------------|----------------------|---------------------------------------------------|
| Anaphylaxis            | mRNA vaccines (BNT162b2 and mRNA-1273) | 11.1 cases per million doses | Immediate generalized IgE-mediated hypersensitivity reaction. Potential allergens: Polyethylene glycol (PEG) (mRNA vaccines) and polysorbate (vector-based vaccines) | Flashing, eruption, urticaria, angioedema, airway and/or breathing and/or cardiovascular compromise | For (confirmed) severe allergic reactions after the first vaccine dose, the Centers for Disease Control and Prevention (CDC) and the World Allergy Organization (WAO) recommend against the administration of second dose and maybe the substitution of an mRNA vaccine with a non-mRNA for the second dose |
| Vaccine-induced Thrombotic Thrombocytopenia | Adenoviral vector-based vaccines (ChAdOx1 CoV-19 and Ad26.COV2.S) | 0.73 cases per 100,000 individuals | Activation of the platelets by the anti-PF4 antibodies, leading to arterial/venous thrombosis and platelet consumption | Arterial and/or venous thrombosis (usually cerebral and abdominal thrombosis) - Low platelet count, high d-dimers (>4 times upper limit of normal) and positive anti-PF4 antibodies | High dose IVIG with or without corticosteroids and non-heparin anticoagulation - In refractory cases, plasma exchange and complement inhibition with ecizulizumab |
| Myocarditis/Péricarditis | mRNA vaccines (BNT162b2 and mRNA-1273) | 12.6 cases per million doses | Molecular mimicry between the viral spike protein and a cardiac protein, as well as induction of immunologic pathways and a non-specific innate inflammatory response | Retrosternal chest pain, often worsened by inspiration and relieved by leaning forward and respiratory distress - High troponin and C-reactive protein levels - ST-segment elevation in the electrocardiogram - Mildly reduced to normal left ventricular ejection fraction and global hypokinesis in transthoracic echocardiogram - Abnormal findings in cardiac MRI | Non-steroidal anti-inflammatory drugs, colchicine and steroids - In patients <18 years old, intravenous immunoglobulin and steroids |
| Guillain-Barré syndrome | Adenoviral vector-based vaccines (ChAdOx1 CoV-19 and Ad26.COV2.S) | Ad26.COV2.S: 7.8 cases per million doses ChAdOx1 CoV-19: 227 cases per 51.4 million doses | Acute or subacute immune-mediated neurologic disease of peripheral nerves that is usually triggered by vaccines - Molecular mimicry, anti-ganglioside antibody production and complement activation | Quadriplegia or Paraplegia - Abnormal spinal cord MRI | Steroids, IVIG2 and/or plasma exchange |
| Acute Transverse Myelitis | Adenoviral vector-based vaccines (ChAdOx1 CoV-19) | Unknown (sporadic cases) | Immune-mediated neurologic disease that is usually triggered by vaccines - Molecular mimicry and bystander immune response activation | Quadruplegia or Paraplegia - Abnormal spinal cord MRI | Steroids, IVIG2 |
| Acute Disseminated Encephalomylitis | mRNA and Adenoviral vector-based vaccines | Unknown (sporadic cases) | Immune-mediated neurologic disease that is usually triggered by vaccines - Molecular mimicry and bystander immune response activation | Abnormal brain and spinal cord MRI - Clinical manifestations of Acute Disseminated Encephalomylitis | Steroids, IVIG2 and/or plasma exchange |
| Bell’s Palsy | mRNA vaccines (BNT162b2 and mRNA-1273) | Unknown (sporadic cases) | Immune-mediated neurologic disease that is usually triggered by vaccines - Molecular mimicry and bystander activation of dormant autoreactive T-cells | Unilateral facial paresis or paralysis | Steroids |
| Rhabdomyolysis | mRNA and Adenoviral vector-based vaccines | Unknown (sporadic cases) | Exaggerated immune response to vaccine adjuvants | Myalgia, weakness and dark urine - High plasma creatine kinase levels and high urine myoglobin | Intravenous hydration - In severe disease, consider urinary alkalinization |

*Anti-PF4: antibodies against platelet factor 4, IVIG: intravenous immunoglobulin.*
immune-mediated neurologic disease of peripheral nerves that is usually as Ad26.COV2.S and ChAdOx1 CoV-19 [36]. GBS is an acute or subacute following vaccinations with adenovirus vector COVID-19 vaccines, such as also used [21]. Without leading to thrombosis; this phenomenon denotes that our un noted that anti-PF4 antibodies - are formed through cross-reaction with vaccine’s antigens - bound and activate the platelets leading to arterial and venous thrombosis and, consequently, to platelet consumption [28–30]. However, it should be noted that anti-PF4-polyanion antibodies are commonly found in other conditions (such as in up to 50% of post cardiac surgery patients) without leading to thrombosis; this phenomenon denotes that our understanding regarding VITT pathogenesis is still insufficient [25]. As it is an immune mediated condition, suggested treatment includes administration of high dose intravenous immunoglobulin (IVIG) with or without corticosteroids and non-heparin anticoagulation [21]. In refractory cases, plasma exchange and complement inhibition with eculizumab have also been used [21].

In June 2021, a possible causal association between SARS CoV-2 mRNA-based vaccines, both BNT162b2 vaccine and mRNA-1273 vaccine, and myocarditis and/or pericarditis, was reported [31]. Since then, there is increasing evidence that myocarditis and pericarditis constitute rare complications of the mRNA vaccines [32]. As of August 18, 2021, Vaccine Adverse Event Reporting System (VAERS) has received 1339 reports of myocarditis or pericarditis among people <30 years old, who received COVID-19 vaccine, but through follow-up, Centers for Disease Control and Prevention (CDC) and FDA have confirmed 778 reports of myocarditis or pericarditis in male adolescents and young adults without any significant cardiovascular co-morbidities [33]. The estimated myocarditis/pericarditis rate was 12.6 cases per million doses of second-dose mRNA vaccine among individuals 12–39 years of age [34], while the adjusted risk ratio for myocarditis and pericarditis events in children and young adults between 16 and 24 years of age has been described to be 0.94 (95%CI 0.59–1.52) [34]. CDC recommendations clearly outline the benefits of COVID-19 vaccination, which outweigh the rare myocarditis and pericarditis risks and, therefore, recommends the vaccination for anyone who is 12 years of age and older [34]. Although the pathophysiologic mechanisms of myocarditis development are not clear, molecular mimicry between the viral spike protein and a cardiac protein, as well as induction of immunologic pathways and a non-specific innate inflammatory response have been proposed [31]. Most patients with post-vaccination myocarditis present retrosternal chest pain, that is often worsened by inspiration and relieved by leaning forward, while some patients develop respiratory distress in addition to the chest pain. Symptom onset is usually within 2–3 days (range 1–7 days) after the second dose of mRNA vaccination [31]. Laboratory investigations show elevation in troponin and C-reactive protein levels that are both indicative of myocardial inflammation. The electrocardiogram is abnormal, demonstrating ST-segment elevation, while transthoracic echocardiogram shows mildly reduced to normal left ventricular ejection fraction and global hypokinesia. Treatment includes non-steroidal anti-inflammatory drugs, colchicine and corticosteroids; in young patients (<18 years old), IVIG (along with corticosteroids) has also been administered [35]. To date, all cases that have been reported in the literature, developed a non-severe disease with complete clinical recovery within 1–3 weeks post myocarditis/pericarditis onset [31,35].

RARE cases of Guillain-Barré syndrome (GBS) have been reported following vaccinations with adenovirus vector COVID-19 vaccines, such as Ad26.COV2.S and ChAdOx1 CoV-19 [36]. GBS is an acute or subacute immune-mediated neurologic disease of peripheral nerves that is usually triggered by infections and is characterized by ascending weakness in limbs or cranial nerves, flaccid paralysis and areflexia, as well as by increased cerebrospinal fluid protein with normal numbers of cells [37, 38]. Within VAERS, 100 reports of GBS following Ad26.COV2.S vaccine were received from February 27th to June 30th, 2021 with approximately 12.2 million of doses administered [36]. The GBS reporting rate was 7.8 cases per million Ad26.COV2.S vaccine doses administered, while it was highest among males aged 50–64 years, with 15.6 cases per million Ad26.COV2.S vaccine doses administered. The median age of patients, who developed GBS after Ad26.COV2.S, was 57 years (range: 24–76), 61% were males, and the median interval between vaccination and symptom onset was 13 days (range: 0–75 days) [39]. Most patients presented clinical recovery and one patient died [39]. A total of 227 cases of GBS were reported after ChAdOx1 CoV-19 vaccine by June 27, 2021, with about 51.4 million doses administered [40]. A study that summarized the data of the patients with GBS after the ChAdOx1 CoV-19 vaccine, reported that all cases developed GBS following the first dose with a latency between 3 and 22 days [41]. The majority showed rare phenotypes such as distal paresthesia or quadriaparesis with facial diplegia; the patients received steroids, IVIG and/or plasma exchange, with a partial recovery [41]. Sporadic cases of GBS have been also reported after the mRNA COVID-19 vaccines [42,43].

In total, 3 cases of acute transverse myelitis (ATM) were reported during the Phase III clinical trial of ChAdOx1 CoV-19 vaccine, two in the vaccine arm and one in the control arm. The second patient with ATM among the two reported cases in the vaccine arm, was not vaccine-related as the patient was diagnosed with pre-existing multiple sclerosis [44]. Since then, random cases of ATM, as well as cases of acute disseminated encephalomyelitis have been described in the literature [45–47]. Besides ATM and acute disseminated encephalomyelitis, 7 cases of bell’s palsy were reported among nearly 40,000 participants in the vaccine arm in the clinical trials investigating efficacy of BNT162b2 and mRNA-1273 vaccines, while only 1 case was reported in the placebo arm [48,49]. This incidence is 3.5–7 times higher than the incidence of general population [48,49]. During post market surveillance, only a few cases of facial palsy following COVID-19 vaccination have been described [50,51]. Finally, rare cases of vaccine-induced rhabdomyolysis have been reported [52]. However, it is worth noting that there is currently no evidence denoting a pathogenetic mechanism between COVID-19 vaccines and these entities.

In conclusion, COVID-19 vaccines are the mainstay for the prevention of this global pandemic. Despite rare cases of complications, the risk-benefit assessment for COVID-19 vaccination shows a clearly favorable balance towards vaccines for all patients that vaccines have been approved irrespectively of age and sex. However, vaccine adverse events should be identified, monitored and followed up with high priority in order to manage them properly. The benefits of COVID-19 vaccines continue to outweigh any potential risk of adverse events. These complications should not be the reason of changing the vaccine policy and further studies are needed to alleviate public concerns and potential reluctance to COVID-19 vaccinations.

Funding

No Funding

CRedit authorship contribution statement

Paraskevi C. Fragkou: Conceptualization, Methodology, Data curation, Writing – original draft, Visualization, Investigation, Supervision, Validation, Writing – review & editing. Dimitra Dimopoulou: Conceptualization, Methodology, Data curation, Writing – original draft, Visualization, Investigation, Supervision, Validation, Writing – review & editing.
Declaration of competing interest
None to declare.

Acknowledgements
No acknowledgements.

References
[1] World Health Organization (WHO). COVID-19 vaccines. https://www.who.int/emergencies/diseases/novel-coronavirus-2019/covid-19-vaccines. [Accessed 29 August 2021].
[2] U.S. Food and Drug Administration (FDA). FDA takes key action in fight against COVID-19 by issuing emergency use authorization for first COVID-19 vaccine. FDA, https://www.fda.gov/news-events/press-announcements/fda-takes-key-action-fight-against-covid-19-issuing-emergency-use-authorization-first-covid-19. August 29, 2021.
[3] European Medicines Agency (EMA). EMA recommends first COVID-19 vaccine for authorisation in the EU. European Medicines Agency; 2021. https://www.ema.europa.eu/en/news/ema-recommends-first-covid-19-vaccine-authorisation-eu. [Accessed 29 August 2021].
[4] Centers for Disease Control and Prevention (CDC). Different COVID-19 vaccines. CDC, 2021. https://www.cdc.gov/coronavirus/2019-ncov/vaccines/different-vaccines.html. [Accessed 29 August 2021].
[5] European Medicines Agency (EMA). COVID-19 vaccines | European Medicines Agency. https://www.ema.europa.eu/en/human-regulatory/overview/public-health-themes/coronavirus-disease-2019-treatments/covid-19-vaccines. [Accessed 29 August 2021].
[6] World Health Organization (WHO). Status of COVID-19 vaccines within WHO EUL/PQ evaluation process manufacturer. WHO EU holder Name of Vaccine NRA of Record Platform EUI accepted Pre-submission meeting held Dossier accepted for review* Status of assessment** Decision date***; 2021. https://extranet.who.int/pqweb/sites/default/files/documents/Status_COVID_VAX_19August2021.pdf. [Accessed 29 August 2021].
[7] COVID-19 Vaccine Tracker, Sinopharm (Beijing): BBIBP-CoV (vero cells) - COVID-19 vaccine tracker. https://covid19.trackvaccines.org/vaccines/5/. [Accessed 29 August 2021].
[8] World Health Organization (WHO). Safety of COVID-19 vaccines. https://www.who.int/news-room/feature-stories/detail/safety-of-covid-19-vaccines. [Accessed 29 August 2021].
[9] Taviiani A, Abbasi E, Kian Ara F, Darini A, Asery Z. COVID-19 vaccines: current evidence and considerations. Metabolism Open 2021;12:100124. https://doi.org/10.1016/j.metabol.2021.100124.
[10] Centers for Disease Control and Prevention (CDC). Management of anaphylaxis at COVID-19 vaccination sites. CDC; 2021. https://www.cdc.gov/vaccines/covid-19/clinical-considerations/managing-anaphylaxis.html. [Accessed 27 October 2021].
[11] World Health Organization Journal 2020;13. https://doi.org/10.1016/J.VACCINE.2020.02.046.
[12] Chansky DJ, Sandler A, Kudlow G, Heset S, Lotze MT, Vyas S, et al. Thrombotic events (SMQ) with Administrative information. https://www.ema.europa.eu/en/human-regulatory/overview/public-health-themes/coronavirus-disease-2019-treatments/covid-19-vaccines. [Accessed 27 October 2021].
[13] Maqrashi ZAA, Shroff A, Lessard MC, Blais N, Kelton JGNI. Adjunct immune globulin for vaccine-induced immune thrombotic thrombocytopenia. N Engl J Med 2021;385:720-8. https://doi.org/10.1056/NEJMOA2107551.
[14] UpToDate. COVID-19: Vaccine-induced immune thrombotic thrombocytopenia-vitt. [Accessed 29 August 2021].
[15] Chan BT, Mpa M, Bobos P, Oduotayo A, Pai M, Chan B, et al. Meta-Analysis of risk of vaccine-induced immune thrombotic thrombocytopenia following ChAdOx1-S recombinant vaccine. Medrxiv 2021. doi:10.1101/ 2021.05.04.21256613.
[16] Schultz NH, Sørvoll IH, Michelsen AE, Munthe LA, Lund-Johansen F, Ahlen MT, et al. Thrombosis and thrombotic thrombocytopenia after ChAdOx1 nCoV-19 vaccination. N Engl J Med 2021;384:2124-30. https://doi.org/10.1056/NEJMOA2104882.
[17] Cines DB, Bussel JB. SARS-CoV-2 vaccine-induced immune thrombotic thrombocytopenia. N Engl J Med 2021;384:2254-6. doi:10.1056/NEJMoa2106315.
[18] Pavord S, Scully M, Hunt BJ, Lester W, Bagot C, Craven B, Ramapota A, Ambler GMM. Clinical features of vaccine-induced immune thrombosis and thrombosis. N Engl J Med 2021. doi:10.1056/NEJMoa2109998.
[19] World Health Organization (WHO). COVID-19 vaccines. https://www.who.int/news-room/feature-stories/detail/safety-of-covid-19-vaccines. [Accessed 29 August 2021].
[20] Simons FE, Ardusso LR, Biller BM. COVID-19 vaccination and autoimmunity. J Neuroimmunol 2021;359:577691. https://doi.org/10.1016/J.JNN.2021.08.007.
[21] BNT162b2 COVID-19 vaccine. Neurol Sci : Official Journal of the Italian Federation of Neurology. 2021. doi:10.1007/s11062-021-04190-6.
[22] Trimboli M, Zoleo P, Arabia G, Gambardella A. Guillain-Barré syndrome following the ChAdOx1 nCoV-19 vaccine: report of two cases and review of the literature. J Neuroimmunol 2021;384:3515–23. https://doi.org/10.1016/J.JNEUIMM.2021.08.007.
[23] UPToDate. COVID-19: Vaccine-induced immune thrombotic thrombocytopenia-vitt. [Accessed 29 August 2021].
[24] Greene J, Hume NR, Sandberg WA, Muehrcke RC, Johnson)
[43] Waheed S, Bayas A, Hindi F, Rizvi Z, Espinosa PS. Neurological complications of COVID-19: gullain-Barre syndrome following pfizer COVID-19 vaccine. Cureus 2021;13. https://doi.org/10.7759/CUREUS.13426.

[44] Knoll MD, Wonodi C. Oxford-AstraZeneca COVID-19 vaccine efficacy. Lancet (London, England) 2021;397:72–4. https://doi.org/10.1016/S0140-6736(20)32623-4.

[45] Ozgen Kenangil G, Ari BC, Guler C, Demir MK. Acute disseminated encephalomyelitis-like presentation after an inactivated coronavirus vaccine. Acta Neurol Belg 2021;121:1089–91. https://doi.org/10.1007/s13760-021-01699-x.

[46] Pagenkopf C, Südmeyer M. A case of longitudinally extensive transverse myelitis following vaccination against Covid-19. J Neuroimmunol 2021:358. https://doi.org/10.1016/j.jneuroim.2021.577606.

[47] Vogrig A, Janes F, Gigli GL, Curcio F, Negro ID, D’Agostini S, Fabris MVM. Acute disseminated encephalomyelitis after SARS-CoV-2 vaccination. Clin Neurol Neurosurg 2021;208:106839. https://doi.org/10.1016/J.CLINNEURO.2021.106839.

[48] Baden LR, El Sahly HM, Essink B, Kotloff K, Frey S, Novak R, Diemert D, Spector SA, Rouphael N, Creech CB, McGettigan J, Khetan S, Segall N, Solis J, Brosa A, Fierro C, Schwartz H, Neuzil K, Corey L, Gilbert P, Janes H, Follmann D, Marovich M, Mascola J, ZTCSG. Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. N Engl J Med 2021;384:403–16. https://doi.org/10.1056/NEJMoa2035389.

[49] Polack FP, Thomas SJ, Kitchin N, Absalon J,urtman A, Lockhart S, Perez JL, Perez Marc G, Moreira ED, Zerbini C, Bailey R, Swanson KA, Roychoudhury S, Koury K, Li P, Kalina WV, Cooper D, Frencj Jr RW, Hammitj LL, Tureci O, Neill H, Schaefer A, Unal S, Tre GWCCGT, Safety and efficacy of the BNT162b2 mRNA covid-19 vaccine. N Engl J Med 2020;383:2603–15. https://doi.org/10.1056/NEJMoa2034577.

[50] Iftikhar H, Noor SMU, Masood M, Bashir K. Bell’s palsy after 24 hours of mRnA-1273 SARS-CoV-2 vaccine. Cureus 2021;13. https://doi.org/10.7759/CUREUS.15935.

[51] Wan EYF, Chui CSL, Lai FTT, Chan EWY, Li X, Yan VKC, Gao L, Yu Q, Lam ICH, Chun RKC, Cowling BJ, Fong WC, Lau AYL, Mok VCT, Chan FLF, Lee CK, Chan LST, Lo D, Lau KK, Hung IFN, Leung GMWI. Bell’s palsy following vaccination with mRNA (BNT162b2) and inactivated (CoronaVac) SARS-CoV-2 vaccines: a case series and nested case-control study. Lancet Infect Dis 2021. https://doi.org/10.1016/S1473-3099(21)00451-5.

[52] Nansar M, Chung H, Dhayaparan Y, Nyein A, Acediado BJ, Chicos C, Zheng D, Barras M, Mohamed M, Alfadhawy M, Nse N, Rizzo VKE. COVID-19 vaccine induced rhabdomyolysis: case report with literature review. Diabetes & Metabolic Syndrome 2021;15:102170. https://doi.org/10.1016/j.dsx.2021.06.007.